Thanks for your interest in Iotron Medical, Inc.
We are the first commercial supplier of Copper-67 and hope you stop by and see us at booth #1026.
As the first commercial supplier of Copper-67, Iotron Medical is committed to quality, quantity, reliability and support. It is our mission to optimize the quality and accessibility of Copper-67 for the radiopharmaceutical community.
Copper-67 is a proven and effective radioisotope for theranostic cancer treatment, particularly when paired with the imaging isotopes Copper-64 or Copper-61. This "perfect pairing" of identical elements delivers key advantages, including:
- Identical in-vivo distribution and behavior - for imaging and therapy
- Patient dose optimization - for personalized medicine
- Optimum half-life for small therapeutics - for dose delivery optimization
- Convenient off-site central manufacturing - for minimal treatment site investment
- No reliance on nuclear reactors for production - for safety and scalability
Iotron Medical is now supplying Copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostic treatments. Stop by our booth (546) at the 2025 SNMMI Annual Meeting to learn more!